US Stock Alert: argenx Plunges on October 8 Due to Termination of Trials, Insufficient Efficacy, and Pipeline Setbacks

argenx October 8 Sharp Decline Interpretation

Keywords: trial termination, lack of efficacy, pipeline setback

1. On October 8, 2026, an interim analysis by the independent data monitoring committee found that the efgartigimod subcutaneous injection failed to meet its primary endpoint in the phase III UNITY trial for Sjögren’s syndrome, and the company therefore decided to terminate the trial; this outcome dampens expectations for expanding Vyvgart’s indication to this disease, although no new safety concerns were identified.

2. On October 8, 2026, although the FB102 phase II trial for celiac disease achieved its primary endpoint, the project remains in mid-stage development and is planned to advance to phase III, making it difficult to offset the impact of the UNITY trial termination on pipeline expectations in the short term.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)